Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Mini-Review Article

Ocular Drug Delivery of Nanoparticles for Glaucoma

In Press, (this is not the final "Version of Record"). Available online 19 February, 2024
Author(s): Aastha Dangwal*, Vikas Bhatt and Shiv Kumar Gupta
Published on: 19 February, 2024

DOI: 10.2174/0115748855278863240130074330

Price: $95

conference banner
Abstract

The nasolacrimal channels drain the medication from the pre-corneal area, causing the majority of the ophthalmic medication to be quickly removed following topical instillation. Over the past thirty years, newer medical techniques, such as in situ gel, nanoparticle, liposome, nanosuspension, microemulsion, iontophoresis, and occuserts have been created in an effort to overcome these challenges. These methods gradually and deliberately boost the drug's bioavailability. This article discusses ocular drug delivery for ophthalmics and its ideal characteristics, and also provides an insight on the use of nanotechnology in the form of nanoparticles used for the treatment of glaucoma in the eyes, employing HPH, ultrasonication/HSH, SE, SED technique, SFM, ME technique, SD method, DE method, PM, FUD, and other techniques to offer continuous and controlled IOP inside the eye chamber, make drug more ocularly bioavailable, and address a few pharmacological difficulties in ophthalmology. The creation of new drug delivery methods is currently gaining popularity, and this can facilitate the development of medicines for diseases that endanger eyesight.

Keywords: IOP - Intra Ocular Pressure, HPH- High Pressure Homogenization, ACG - Angle-closure glucoma, OAG - open-angle glucoma, SLN - Solid Lipid Nanoparticles, HSH - High Speed Homogenization


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy